Gotistobart

戈替苏拜单抗

Report date: 2026/03/31 20:00:21

Base Information

Drug NameGotistobart
Drug Alias NameA humanized anti-CTLA4 IgG1 monoclonal antibodyONC-392BNT316BNT-316
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsAnorectal disordersMetastatic breast cancerGastroesophageal Junction Neoplasms +[25] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesOncoimmune Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAcroImmune GroupPfizer IncBiontech Se +[4] 
Inactive CompaniesN/A
Active IndicationsAnorectal disordersMetastatic breast cancerGastroesophageal Junction Neoplasms +[25] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A